AR113069A1 - VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa - Google Patents

VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa

Info

Publication number
AR113069A1
AR113069A1 ARP180102666A ARP180102666A AR113069A1 AR 113069 A1 AR113069 A1 AR 113069A1 AR P180102666 A ARP180102666 A AR P180102666A AR P180102666 A ARP180102666 A AR P180102666A AR 113069 A1 AR113069 A1 AR 113069A1
Authority
AR
Argentina
Prior art keywords
antibodies
variants
bind tnfa
tnfa
bind
Prior art date
Application number
ARP180102666A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of AR113069A1 publication Critical patent/AR113069A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a anticuerpos que se unen a TNFa y exhiben unión a FcRn modificada. Los anticuerpos tienen buenas funciones efectoras y/o propiedades farmacocinéticas. Ácido nucleico, composición farmacéutica y método de tratamiento.
ARP180102666A 2017-09-19 2018-09-19 VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa AR113069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17191988.9A EP3456737B1 (en) 2017-09-19 2017-09-19 Antibody variants

Publications (1)

Publication Number Publication Date
AR113069A1 true AR113069A1 (es) 2020-01-22

Family

ID=59923274

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102666A AR113069A1 (es) 2017-09-19 2018-09-19 VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa

Country Status (16)

Country Link
US (1) US20200255511A1 (es)
EP (2) EP3456737B1 (es)
JP (2) JP7341127B2 (es)
KR (1) KR20200052307A (es)
CN (1) CN111108122B (es)
AR (1) AR113069A1 (es)
AU (1) AU2018335083A1 (es)
BR (1) BR112020005398A2 (es)
CA (1) CA3074249A1 (es)
EA (1) EA202090727A1 (es)
ES (1) ES2978167T3 (es)
IL (1) IL272951A (es)
MX (1) MX2020002942A (es)
SG (1) SG11202001465WA (es)
TW (1) TWI818923B (es)
WO (1) WO2019057565A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
PL3219726T3 (pl) * 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty

Also Published As

Publication number Publication date
EA202090727A1 (ru) 2020-06-15
IL272951A (en) 2020-04-30
EP3456737A1 (en) 2019-03-20
CN111108122B (zh) 2024-08-20
KR20200052307A (ko) 2020-05-14
BR112020005398A2 (pt) 2020-09-29
SG11202001465WA (en) 2020-04-29
JP2023109960A (ja) 2023-08-08
AU2018335083A1 (en) 2020-04-02
EP3684808A1 (en) 2020-07-29
CN111108122A (zh) 2020-05-05
MX2020002942A (es) 2020-07-22
EP3456737B1 (en) 2024-02-14
TWI818923B (zh) 2023-10-21
CA3074249A1 (en) 2019-03-28
JP7341127B2 (ja) 2023-09-08
JP2020534000A (ja) 2020-11-26
TW201915019A (zh) 2019-04-16
US20200255511A1 (en) 2020-08-13
WO2019057565A1 (en) 2019-03-28
ES2978167T3 (es) 2024-09-06

Similar Documents

Publication Publication Date Title
CL2019003796A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas.
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
MA47612A (fr) Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
EA202091540A1 (ru) Антитела к lilrb2
MA43186A (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
BR112018067458A2 (pt) anticorpos para tigit
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CU24613B1 (es) Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
CU20170169A7 (es) Anticuerpos de factor xi
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
DK3381469T3 (da) Anti-erbb2 antistoflægemiddelskonjugat og sammensætning deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf
UA117364C2 (uk) Похідні аматоксину
DK3242892T3 (da) Modificerede april-bindende antistoffer
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels